US Edition
COI statement prohibits “unseemly advocacy,” “undue influence” by industry rep on ODAC - The Cancer Letter
Summary by The Cancer Letter
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
COI statement prohibits “unseemly advocacy,” “undue influence” by industry rep on ODAC - The Cancer Letter
In April, FDA Commissioner Marty Makary said that the presence of industry employees as members of FDA advisory committees “represents a cozy relationship” between FDA and the businesses it regulates. This content is for Group 1 - Individual Seat, Individual Subscription - Annual ($555), Individual Subscription - Monthly ($55), Introductory Subscription - non-renewing ($60), and Sponsored account members only. Visit the site and log in/register …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
